Benzinga | Oct 28, 2021 09:16AM EDT

Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100

Credit Suisse analyst Tiago Fauth maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $102 to $100.